The protocol evaluates compounds to determine their antiviral activity against coronaviruses. The antiviral activity is evaluated based on the 50% inhibitory concentration (IC50) and the 50% effective concentration (EC50). Two cell lines can be used for these assays (A549+ACE2+TMP (Invivogen) or VeroE6/TMPRSS2 cells (XenoTech)). The multiplicity of infection (MOI) will depend on the virus stock titer. The incubation time can vary if using a reporter virus. The assay can be performed in 96-well plates (medium throughput screening) or 384-well plates (high throughput screening).
Álvarez et al. (Mon,) studied this question.